

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: PETER B. DERVAN

Title: INHIBITION OF ONCOGENE
TRANSCRIPTION BY SYNTHETIC
POLYAMIDES


Appl. No.: 09/807,354

Intnl. Appl. No. PCT/US99/20489

Filing Date: 10 September 1999

Examiner: TBA

Art Unit: 1648

<p>CERTIFICATE OF EXPRESS MAILING</p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service's "Express Mail Post Office To Addressee" service under 37 C.F.R. § 1.10 on the date indicated below and is addressed to: Commissioner for Patents, 2900 Crystal Drive, Arlington, VA 22202-3513</p> <p>Suzanne L. Simpson (Printed Name)</p> <p> (Signature)</p> <p>11/21/01 (Date of Deposit)</p>

**AMENDMENT TO SPECIFICATION IN RESPONSE
TO NOTICE OF MISSING REQUIREMENTS**

Commissioner for Patents
Box Sequence Listing
Washington, D.C. 20231

Sir:

Please amend the subject application as follows:

In the specification:

At page 4 replace the paragraph starting on line 10 with:

Other small molecules have also been of interest as DNA-binding ligands. Wade, *et al.* reported the design of peptides that bind in the minor groove of DNA at 5'-(A,T)G(A,T)C(A,T)-3' sequences by a dimeric side-by-side motif (*J. Amer. Chem. Soc.*) **114**, 8783-8794 (1992)). Mrksich, *et al.* reported antiparallel side-by-side motif for sequence specific-recognition in the minor groove of DNA by the designed peptide I-methylimidazole-2-carboxamidenetropsin (*Proc. Natl. Acad. Sci. USA* **89**, 7586-7590 (1992)). Pelton, J.G. & Wemmer, D.E. reported the structural characterization of a 2-1 distamycin A-d